桑叶新型活性化合物及其抗糖尿病机制研究
本研究探讨桑叶总黄酮(MLF)和桑叶多糖(MLP)对2型糖尿病模型ob/ob小鼠的降糖作用,并与桑枝生物碱(RMA)比较。网络药理学、分子对接及细胞实验表明,MLF主要活性成分morusin、kuwanon C和morusyunnansin L通过PI3K-Akt等通路改善胰岛素抵抗,morusin可抑制ADORA1和PPARG基因表达。
要点
- MLF和MLP可改善胰岛素抵抗肝细胞的葡萄糖摄取,并缓解ob/ob小鼠胰岛素抵抗和糖耐量异常。
- RMA不影响肝内脂质积累,而MLF和MLP的作用机制涉及PI3K-Akt、脂质与动脉粥样硬化及AGE-RAGE通路。
- morusin、kuwanon C和morusyunnansin L与ADORA1、AKT1、PPARγ、GSK3β等靶点高亲和力结合。
核心结论
- 桑叶总黄酮(MLF)和桑叶多糖(MLP)可改善ob/ob小鼠的胰岛素抵抗和糖耐量异常,MLF活性成分morusin、kuwanon C和morusyunnansin L可能成为治疗T2DM的候选药物。
研究设计与样本
- 研究采用ob/ob小鼠(2型糖尿病动物模型)比较MLF、MLP与桑枝生物碱(RMA)的降糖效果,并结合网络药理学、分子对接、胰岛素抵抗细胞模型和qPCR验证。
主要发现
- MLF和MLP改善胰岛素抵抗肝细胞的葡萄糖摄取;MLF、MLP和RMA均缓解ob/ob小鼠胰岛素抵抗和糖耐量异常,但RMA不影响肝内脂质积累。
- 网络药理学分析显示MLF主要活性成分为morusin、kuwanon C和morusyunnansin L,通过PI3K-Akt信号通路、脂质与动脉粥样硬化通路及AGE-RAGE信号通路改善胰岛素抵抗和血糖。
- RMA主要活性成分为1-脱氧野尻霉素(DNJ)、fagomine(FA)和N-甲基-1-脱氧野尻霉素,靶向碳水化合物代谢并调节α-葡萄糖苷酶活性。
- 分子对接显示morusin、kuwanon C和morusyunnansin L与ADORA1、AKT1、PPARγ和GSK3β高亲和力结合;morusin通过抑制ADORA1和PPARG基因表达改善肝细胞胰岛素抵抗。
临床怎么用
- 桑叶总黄酮及其活性成分morusin、kuwanon C、morusyunnansin L可能作为T2DM管理的潜在药物先导化合物,但需进一步临床研究验证。
局限性
- 研究仅基于ob/ob小鼠模型和体外细胞实验,尚未在人体中验证MLF及其活性成分的降糖疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mulberry (Morus alba L.) leaves have long been considered beneficial in traditional Chinese medicine to treat infectious and internal diseases. Recently studies have discovered that the mulberry leaf's total flavonoids (MLF) display excellent hypoglycemia properties. However, the active ingredients and their molecular mechanisms are still uncharacterized. In this study, we explored the hypoglycemic effects of MLF and mulberry leaf polysaccharides (MLP) on ob/ob mice, an animal model of type 2 diabetes mellitus (T2DM), compared with Ramulus Mori (Sangzhi) alkaloid (RMA). Network pharmacology was employed to identify the potential available targets and active compounds of MLF and RMA against hyperglycemia. Molecular docking, an insulin-resistant cell model and qPCR were employed to verify the antidiabetic activity of the critical compounds and the gene expression profiles of the top molecular targets. Here, the results showed that MLF and MLP improved glucose uptake in insulin-resistant hepatocytes. MLF, MLP and RMA alleviated insulin resistance and glucose intolerance in ob/ob mice. Unlike MLF and MLP, RMA administration did not influence the accumulation of intrahepatic lipids. Network pharmacology analysis revealed that morusin, kuwanon C and morusyunnansin L are the main active compounds of MLF and that they amend insulin resistance and glycemia via the PI3K- Akt signaling pathway, lipid and atherosclerosis pathways, and the AGE-RAGE signaling pathway. Moreover, 1-deoxynojirimycin (DNJ), fagomine (FA), and N-methyl-1-deoxynojirimycin are the primary active ingredients of RMA and target carbohydrate metabolism and regulate alpha-glucosidase activity to produce a potent anti-diabetic effect. The molecular docking results indicated that morusin, kuwanon C and morusyunnansin L are the critical bioactive compounds of MLF. They had high affinities with the key targets adenosine A1 receptor (ADORA1), AKT serine/threonine kinase 1 (AKT1), peroxisome proliferator-activated receptor gamma (PPARγ), and glycogen synthase kinase 3 beta (GSK3β), which play crucial roles in the MLF-mediated glucose-lowering effect. Additionally, morusin plays a role in amending insulin resistance of hepatocytes by repressing the expression of the ADORA1 and PPARG genes. Our results shed light on the mechanism behind the glucose-lowering effects of MLF, suggesting that morusin, kuwanon C, and morusyunnansin L might be promising drug leads for the management of T2DM.
引用
- Lv Q, Lin J, Wu X, et al. Novel active compounds and the anti-diabetic mechanism of mulberry leaves. Front Pharmacol. 2022. PMID: 36278175. doi:10.3389/fphar.2022.986931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。